Solid Dosage Products: Tracking the Market

What are key moves and trends by CDMOs/CMOs and suppliers in the oral solid-dosage market? A look at key market and technology developments.

Solid growth
The global oral solid dosage (OSD) contract manufacturing market is expected to reach $54.7 billion by 2030 and expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030, according to a recent analysis by Grand View Research. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

The tablets segment dominated the market with a revenue share of 32.7% in 2023. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth

The controlled-release segment accounted for the largest share with 52.2% in 2023. This growth is attributed to advancements in oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for controlled-release dosage forms is anticipated to boost segmental revenue growth in the near future

Based on end-use, the large-size companies segment accounted for the largest share in 2023 with a 54.8% share, according to Grand View Research The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption

Asia-Pacific led the global market in 2023 on a geographic growth basis and is projected to see the fastest CAGR of 6.3% during the forecast years, led by growth in China and India. Expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea will also contribute to growth in the region.

Recent Feature Articles

US Government Moves To Counter Ex-US R&D

By
FDA announced plans to increase oversight of clinical trials overseas while proposing a pilot to shorten and remove barriers in the IND process as a means to increase US-based research and counter shifts to ex-US R&D.
Money-pills-flag

The Next Round in US Drug Pricing & Mfg Investments

By
The White House has signed nine new deals for most-favored-nation drug pricing with mid-sized pharma companies, bringing the total of such deals to 26 along with more committments for US-based manufacturing. 

Supply Planning: Are Foreign-Trade Zones the Right Tool?

By
Amid evolving trade policies, foreign-trade zones are a potential tool to support companies’ supply-chain strategies, but how can they be used?

Primary Packaging: The Moves and Capacity Additions

By
What have been the major moves—mergers and acquisitions and capacity additions in primary packaging? The latest developments and trends.